ISBN: 9789048181568

History of Research on Tumor Angiogenesis Please note: this item is printed on demand and will take extra time before it can be dispatched to you (up to 20 working days).Author(s): Dom… Meer...

History of Research on Tumor Angiogenesis Please note: this item is printed on demand and will take extra time before it can be dispatched to you (up to 20 working days).Author(s): Domenico RibattiFormat: PaperbackPublisher: Springer, NetherlandsImprint: SpringerISBN-13: 9789048181568, 978-9048181568SynopsisIn 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis.Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy.This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors., Nieuw, Festpreisangebot, [LT: FixedPrice], Book Title: History of Research on Tumor Angiogenesis, EAN: 9789048181568, Publication Year: 2010, Type: Textbook, Language: English, Publication Name: History of Research on Tumor Angiogenesis, Item Height: 235mm, Item Width: 155mm, Subject: Medicine, Science, Biology, Item Weight: 220g, Number of Pages: 126 Pages, Springer<

2010, ISBN: 9048181569

[EAN: 9789048181568], Nieuw boek, [SC: 13.94], [PU: Springer Netherlands], MONOCLONALANTIBODIES; TISSUE; TRANSPLANTATION; TUMORGROWTH, Besorgungstitel Neuware - Rare Book Procurement - In… Meer...

[EAN: 9789048181568], Nieuw boek, [SC: 13.94], [PU: Springer Netherlands], MONOCLONALANTIBODIES; TISSUE; TRANSPLANTATION; TUMORGROWTH, Besorgungstitel Neuware - Rare Book Procurement - In 1971, J. Folkman published in the 'New England Journal of Medicine' a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis.Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy.This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors. 136 pp. Englisch, Books<

2004, ISBN: 9789048181568

In 1971, J. Folkman published in the â??New England Journal of Medicineâ? a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably se… Meer...

In 1971, J. Folkman published in the â??New England Journal of Medicineâ? a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980â??s, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors. Books > Biomedicine Soft cover, Springer Shop<

2004, ISBN: 9789048181568

In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors proba… Meer...

In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis.Beginning in the 1980''s, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy.This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors. Books List_Books<

2010, ISBN: 9789048181568

auteur: Ribatti, Domenico, Springer, Paperback, Auflage: Softcover reprint of hardcover 1st ed. 2009, 136 Seiten, Publiziert: 2010-10-19T00:00:01Z, Produktgruppe: Book, Hersteller-Nr.: bi… Meer...

auteur: Ribatti, Domenico, Springer, Paperback, Auflage: Softcover reprint of hardcover 1st ed. 2009, 136 Seiten, Publiziert: 2010-10-19T00:00:01Z, Produktgruppe: Book, Hersteller-Nr.: biography, 0.45 kg, Nosologie, Basiswetenschappen, Geneeskunde & verpleging, Categorieën, Boeken, Oncologie, Interne geneeskunde, Pathologie, Specialismen, Moleculaire biologie, Biologie, Biologische wetenschappen, Wetenschap, natuur & wiskunde, Celbiologie, Geschiedenis van de wetenschap, Engelstalige boeken, Specialty Stores, Springer, 2010<